A century-old debate on protein aggregation and neurodegeneration enters the clinic

Peter T. Lansbury, Hilal A. Lashuel

Research output: Contribution to journalArticle

479 Citations (Scopus)

Abstract

The correlation between neurodegenerative disease and protein aggregation in the brain has long been recognized, but a causal relationship has not been unequivocally established, in part because a discrete pathogenic aggregate has not been identified. The complexity of these diseases and the dynamic nature of protein aggregation mean that, despite progress towards understanding aggregation, its relationship to disease is difficult to determine in the laboratory. Nevertheless, drug candidates that inhibit aggregation are now being tested in the clinic. These have the potential to slow the progression of Alzheimer's disease, Parkinson's disease and related disorders and could, if administered presymptomatically, drastically reduce the incidence of these diseases. The clinical trials could also settle the century-old debate about causality.

Original languageEnglish
Pages (from-to)774-779
Number of pages6
JournalNature
Volume443
Issue number7113
DOIs
Publication statusPublished - 19 Oct 2006
Externally publishedYes

Fingerprint

Proteins
Causality
Neurodegenerative Diseases
Parkinson Disease
Alzheimer Disease
Clinical Trials
Incidence
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

A century-old debate on protein aggregation and neurodegeneration enters the clinic. / Lansbury, Peter T.; Lashuel, Hilal A.

In: Nature, Vol. 443, No. 7113, 19.10.2006, p. 774-779.

Research output: Contribution to journalArticle

Lansbury, Peter T. ; Lashuel, Hilal A. / A century-old debate on protein aggregation and neurodegeneration enters the clinic. In: Nature. 2006 ; Vol. 443, No. 7113. pp. 774-779.
@article{fd9f1d87111c4ce9874008c6be75319f,
title = "A century-old debate on protein aggregation and neurodegeneration enters the clinic",
abstract = "The correlation between neurodegenerative disease and protein aggregation in the brain has long been recognized, but a causal relationship has not been unequivocally established, in part because a discrete pathogenic aggregate has not been identified. The complexity of these diseases and the dynamic nature of protein aggregation mean that, despite progress towards understanding aggregation, its relationship to disease is difficult to determine in the laboratory. Nevertheless, drug candidates that inhibit aggregation are now being tested in the clinic. These have the potential to slow the progression of Alzheimer's disease, Parkinson's disease and related disorders and could, if administered presymptomatically, drastically reduce the incidence of these diseases. The clinical trials could also settle the century-old debate about causality.",
author = "Lansbury, {Peter T.} and Lashuel, {Hilal A.}",
year = "2006",
month = "10",
day = "19",
doi = "10.1038/nature05290",
language = "English",
volume = "443",
pages = "774--779",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7113",

}

TY - JOUR

T1 - A century-old debate on protein aggregation and neurodegeneration enters the clinic

AU - Lansbury, Peter T.

AU - Lashuel, Hilal A.

PY - 2006/10/19

Y1 - 2006/10/19

N2 - The correlation between neurodegenerative disease and protein aggregation in the brain has long been recognized, but a causal relationship has not been unequivocally established, in part because a discrete pathogenic aggregate has not been identified. The complexity of these diseases and the dynamic nature of protein aggregation mean that, despite progress towards understanding aggregation, its relationship to disease is difficult to determine in the laboratory. Nevertheless, drug candidates that inhibit aggregation are now being tested in the clinic. These have the potential to slow the progression of Alzheimer's disease, Parkinson's disease and related disorders and could, if administered presymptomatically, drastically reduce the incidence of these diseases. The clinical trials could also settle the century-old debate about causality.

AB - The correlation between neurodegenerative disease and protein aggregation in the brain has long been recognized, but a causal relationship has not been unequivocally established, in part because a discrete pathogenic aggregate has not been identified. The complexity of these diseases and the dynamic nature of protein aggregation mean that, despite progress towards understanding aggregation, its relationship to disease is difficult to determine in the laboratory. Nevertheless, drug candidates that inhibit aggregation are now being tested in the clinic. These have the potential to slow the progression of Alzheimer's disease, Parkinson's disease and related disorders and could, if administered presymptomatically, drastically reduce the incidence of these diseases. The clinical trials could also settle the century-old debate about causality.

UR - http://www.scopus.com/inward/record.url?scp=33750361540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750361540&partnerID=8YFLogxK

U2 - 10.1038/nature05290

DO - 10.1038/nature05290

M3 - Article

VL - 443

SP - 774

EP - 779

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7113

ER -